EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Therapeutic Potential of Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Narrative Review

Aleksandra Złotowska iD, Wiktoria Hanna Buzun, Karolina Pełka, Zuzanna Zalewska, Wiesława Duszyńska iD

Journal of Clinical Medicine · 27.11.2025 · 14 (23) · 8415

DOI: 10.3390/jcm14238415 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 27.11.2025. Verfasst von Aleksandra Złotowska und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Students Scientific Association by Department and Clinic of Anaesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical Universit…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Increasing antimicrobial resistance (AMR) is one of the leading causes of death worldwide. The predominant pathogens that exacerbate the AMR problem are multidrug-resistant (MDR) Gram-negative bacteria (GNB). Due to the increasing adaptation of MDR GNB to commercially available antimicrobial drugs, such as carbapenems as well as third- and fourth-generation cephalosporins, pharmaceutical companies around the world have been forced to produce increasingly innovative chemotherapeutics. Cefiderocol (CFDC) is a novel injectable cephalosporin 5 generation developed by Shionogi, directed against MDR GNB, including strains resistant to carbapenems.

Results

Analysis demonstrated its significant efficacy across a wide range of in vitro and in vivo studies against MDR GNB, including Carbapenem-resistant Pseudomonas aeruginosa (CRPA), Carbapenem-resistant Acinetobacter baumannii (CRAB), and carbapenem-resistant Enterobacterales (CRE) (WHO Critical Priority Pathogens). Clinical studies have shown CFDC to be an effective drug with few adverse effects.

Conclusions

When used CFDC appropriately within antibiotic stewardship guidelines, this drug is an effective, well-tolerated targeted treatment option for patients with severe clinical conditions.

Schlagwörter

Stichwörter der Autor:innen

Gram-negative bacteriaMDRantimicrobial resistancecefiderocolsiderophore cephalosporinβ-lactam antibiotics

Autor:innen und Institutionen

  • The Students Scientific Association by Department and Clinic of Anaesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University, L. Pasteura Street 1, 50-367 Wroclaw, Poland.
  • Department and Clinic of Anaesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University, L. Pasteura Street 1, 50-367 Wroclaw, Poland.

ORCID-Profile: Aleksandra Złotowska, Wiesława Duszyńska

Zitieren

APA

Złotowska, A., Buzun, W. H., Pełka, K., Zalewska, Z., & Duszyńska, W. (2025). The Therapeutic Potential of Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Narrative Review. Journal of Clinical Medicine, 14(23), 8415. https://doi.org/10.3390/jcm14238415

Vancouver

Złotowska A, Buzun WH, Pełka K, Zalewska Z, Duszyńska W. The Therapeutic Potential of Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Narrative Review. Journal of Clinical Medicine. 2025;14(23):8415. doi:10.3390/jcm14238415

BibTeX
@article{Zotowska2025,
  author = {Złotowska, Aleksandra and Buzun, Wiktoria Hanna and Pełka, Karolina and Zalewska, Zuzanna and Duszyńska, Wiesława},
  title = {The Therapeutic Potential of Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Narrative Review},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {23},
  pages = {8415},
  doi = {10.3390/jcm14238415}
}
Kostenlos starten →